About Business Network
(SPIMACO) the Saudi Joint-Stock Company Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) has a fully paid-up capital of SR 1,200,000,000. It began in the year 1986. The development, production, and marketing of pharmaceutical items and medical equipment are the core business of SPIMACO Addwaeih. Additionally, SPIMACO owns a variety of limited partnerships and joint stock firms both inside and outside the Kingdom. With a solid base to service export markets and a developed strong presence in Saudi Arabia, SPIMACO is well-positioned to maintain its expansion.
Al-Qassim Pharmaceutical Plant, SPIMACO’s primary manufacturing facility, was developing, built, and fitted to the highest standards. Numerous national quality awards and significant international certifications have earned by SPIMACO.
Through internal development and strategic partnerships, SPIMACO ADDWAEIH is committed to providing high-quality pharmaceutical products of international standards that win the loyalty of its customers for the benefit of its shareholders, employees, and society.
SPIMACO ADDWAEIH is to be leader locally and active globally.
SPIMACO ADDWAEIH is deeply committed to meeting patients’ requirements and providing the appropriate medication at the right moment because it believes it has a responsibility to patients.
Because SPIMACO ADDWAEIH values its clients and cares about their demands, it is committed to collaborating closely with them to understand their wants and requirements and to offering high-quality products that live up to their expectations and win their loyalty.
SPIMACO ADDWAEIH is committed to effectively serving society because it believes in its obligation to the community in which it operates.
SPIMACO ADDWAEIH devotes itself to making regular investments in technology as well as utilising new management strategies because it understands how essential it is to boost the efficiency of its performance in order to accomplish its goals for the smallest amount of money.
Employees Empowerment & Development:
SPIMACO ADDWAEIH is commit to recruiting and keeping people with high qualifications, as well as encouraging and educating its staff to advance their knowledge, skills, and abilities and provide them to offer outstanding services to its customers. SPIMACO ADDWAEIH recognises the value of its employees in achieving its goals and in its growth. Staff performance ought to be effective, outstanding in terms of professionalism, and loyal.
Continuous Quality Improvement:
In order to maintain the highest standards of quality on its goods through all stages of development, manufacture, warehousing, and marketing, SPIMACO ADDWAEIH is committed to its conviction that it has a responsibility to patients, healthcare professionals, and the community in which it operates.
SPIMACO ADDWAEIH is mindful of the value of collaboration for company growth and team success in order to continually improve organisational performance.
Due to its faith in its duty to its shareholders and gratitude for their trust in the company, SPIMACO ADDWAEIH is committed to giving them a suitable return on their investments.
QUALITY IN SPIMACO
Quality beyond Compliance
By integrating quality standards into all operational areas of the company, SPIMACO ADDWAEIH is aware of its duty to satisfy customer needs and aspirations. In Saudi Arabia, Has also built up a solid position in terms of growth, serving export markets, and as a preferred partner in regional and global alliances.
The primary SPIMACO ADDWAEIH pharmaceutical manufacturing facility is found at Qassim Plant. It makes use of innovative methods to produce high-quality, safe, and effective medicines. Supply-chain management and product life cycle efficiency have profited from significant investment in modern equipment and technology.
SPIMACO ADDWAEIH recognises its responsibility to meet the demands and expectations of its customers and implements quality standards into all parts of its operations. Additionally, SPIMACO has built a strong position in Saudi Arabia in terms of export market service, growth, and as a top choice for partners in regional and international alliances.
Qassim Plant is home to the main SPIMACO ADDWAEIH pharmaceutical production facility. It employs modern methods to create high-quality, secure, and efficient medications. Significant investments in modern machinery and technology have improved supply-chain management and the effectiveness of the product life cycle.
With the aid of modern equipment and a highly competent and knowledgeable staff, the Product Development Centre allows for the scientific formulation and analytical development of high-quality goods.
This central force uses most advanced industrial quality standards and expertise to produce products that are high-quality, safe, and efficient.
Products made with focus. It is morally committed to offering services and producing goods that consistently conform to national and international standards. To ensure product quality, SPIMACO does product stability studies, bio-equivalence tests, and other procedures.
Product pipeline comprised of the following dosage forms:
- Tablets, Capsules
- Dry Powder for suspension
- Syrups and Suspensions
- Creams, Ointments and Gels
- Mouthwash, Antiseptic products
What is pharmacovigilance?
“The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems” is how pharmacovigilance is defined”.
What is adverse drug reaction (ADR)?
ADR is defined as “a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man”.
Do drugs cause adverse drug reactions (ADRs)?
On the theoretical level, all medications might result in some ADRs, although many people take drugs without experiencing any. In general, the advantages of using a medicine outweigh the possible hazards.
Why do we report adverse drug reaction?
By reporting adverse drug reactions, you help SPIMACO’s pharmacovigilance professionals gather safety data for each drug so they can take the necessary steps to reduce the risk of these ADRs occurring again.
The data you provide will also assist us in fulfilling our duty to notify regulatory agencies of adverse drug reactions. Which will ultimately enhance the standard of community healthcare delivered.
Who can report?
All members of society can report ADRs.
How to report ADRs?
Send the ADR reporting form to the Pharmacovigilance Division after physically or digitally filling it out.
You can also give us a call and we’ll be happy to fill out the form on your behalf.